Israel Englander’s Revolution Medicines RVMD Stock Holding History

Israel Englander’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.35M	Buy	+44,600	New	+$6.51M	﹤0.01%	2477
2026 Q1	–	Sell	-35,000	Closed	-$2.79M	–	6296
2025 Q4	$2.79M	Sell	35,000 -46,000	-57%	-$3.02M	﹤0.01%	3635
2025 Q3	$3.78M	Buy	+81,000	New	+$3.17M	﹤0.01%	3425
2025 Q1	–	Sell	-20,000	Closed	-$875K	–	6331
2024 Q4	$875K	Sell	20,000 -45,000	-69%	-$2.27M	﹤0.01%	4309
2024 Q3	$2.95M	Buy	65,000 +27,400	+73%	+$1.19M	﹤0.01%	3337
2024 Q2	$1.46M	Sell	37,600 -92,400	-71%	-$3.45M	﹤0.01%	3797
2024 Q1	$4.19M	Buy	130,000 +108,800	+513%	+$3.22M	﹤0.01%	3052
2023 Q4	$608K	Sell	21,200 -97,800	-82%	-$2.35M	﹤0.01%	4524
2023 Q3	$3.29M	Buy	119,000 +35,000	+42%	+$1.04M	﹤0.01%	3112
2023 Q2	$2.25M	Buy	+84,000	New	+$2.06M	﹤0.01%	3373
2023 Q1	–	Sell	-95,300	Closed	-$2.27M	–	6786
2022 Q4	$2.27M	Buy	95,300 +35,000	+58%	+$744K	﹤0.01%	3467
2022 Q3	$1.19M	Buy	+60,300	New	+$1.33M	﹤0.01%	4188

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Israel Englander's RVMD Position: Q2 2026 in Review

Israel Englander reduced its Revolution Medicines (RVMD) stake by 43% in Q2 2026, selling an estimated $23.5M and leaving 216,208 shares worth $40.5M. The position accounts for 0.01% of the portfolio, ranked #1031.

Israel Englander first reported a position in RVMD in Q1 2020 and has held it in 21 quarters since. The position peaked at $63.7M in Q4 2025. 688 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Israel Englander held 216,208 shares of Revolution Medicines worth $40.5M as of Q2 2026.
Israel Englander sold 161,124 Revolution Medicines shares in Q2 2026, an estimated $23.5M.
Revolution Medicines made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1031 holding.
Israel Englander first reported a position in Revolution Medicines in Q1 2020 and has held it in 21 quarters since.
Israel Englander's Revolution Medicines position peaked at $63.7M in Q4 2025.
688 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.